Intramyocardial Bone Marrow Cell Therapy, Blinded IDE Study

Hawaii rates for HCPCS C9782

Blinded procedure for New York Heart Association (NYHA) Class II or III heart failure, or Canadian Cardiovascular Society (CCS) Class III or IV chronic refractory angina; transcatheter intramyocardial transplantation of autologous bone marrow cells (e.g., mononuclear) or placebo control, autologous bone marrow harvesting and preparation for transplantation, left heart catheterization including ventriculography, all laboratory services, and all imaging with or without guidance (e.g., transthoracic echocardiography, ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study

Rates data updated October 2026.

How much rates vary

Facilitymedian $4,365 · 10th to 90th $2,818 to $14,791

Distribution of negotiated rates across all payers (price axis is log-scale). Small sample; interpret with caution. Need provider-level prices or 24+ months of history? Contact us.

Rates by insurance carrier

Insurance Carrier	Facility/Professional	Modifier	Typical Low	Median	Typical High
Aetna Setting Facility Modifier None Typical Low $2,818.38 Median $2,818.38 Typical High $2,818.38	Facility	None	$2,818.38	$2,818.38	$2,818.38
United Setting Facility Modifier None Typical Low $4,365.16 Median $4,466.84 Typical High $14,791.08	Facility	None	$4,365.16	$4,466.84	$14,791.08